The gut microbiome is increasingly being recognised as a key regulator of metabolic health and healthy ageing, driving innovation beyond traditional digestive wellness solutions. Emerging research highlights that targeted microbiome interventions—including prebiotics, probiotics, postbiotics, and next-generation biotics—can enhance short-chain fatty acid (SCFA) production, improve gut barrier integrity, reduce chronic low-grade inflammation, and support glucose metabolism, immune function, and metabolic resilience. As scientific understanding of the gut–metabolism axis continues to evolve, the nutraceutical industry is shifting toward evidence-based microbiome solutions that promote not only longevity but also an extended healthspan.